Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer


Lead sponsor: Copharos

Source Copharos
Brief Summary

The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when used with planar and SPECT imaging for the detection of lung cancer and brain cancer consistent with metastatic lung cancer.

Overall Status Unknown status
Phase Phase 1
Study Type Interventional

Intervention type: Drug

Intervention name: 111In-DAC

Intervention type: Procedure

Intervention name: Diagnostic



Inclusion Criteria

Patients will be eligible for the study if they:

- Are male or non-pregnant, non-lactating females 18 years of age or older (must agree to use an appropriate and effective method of birth control during the study and for 2 weeks after study)

- Have an ECOG performance status of Zero or One

- Are being evaluated for known or suspected non-small-cell lung cancer (NSCLC), or known brain lesions consistent with metastatic lung cancer

- (For NSCLC patients)Have been previously scheduled for biopsy or surgical excision of the suspected NSCLC, or have a pathological diagnosis of lung cancer within 2 months of enrollment but have received no previous treatment

- (For brain cancer patients) Have clinical signs and symptoms consistent with a primary NSCLC with histological or cytopathological confirmation. Patients cannot have received previous treatment with radiation to the brain.

- Have signed an informed consent form

Exclusion Criteria

Patients will not be eligible for this study if they:

- Have a history or suspicion of significant allergic reaction or anaphylaxis to any of the 111In-DAC components

- Have a clinically unstable medical condition or opportunistic infection, a life-threatening disease state, impaired renal or hepatic function or are immunosuppressed

- Are taking or have taken part in any investigational study within 30 days of start of study

- Have received an indium agent within 30 days of start of study

- Are not able to remain immobile during scanning time

- Have taken drugs that may damage the kidneys within 2 weeks of start of study

- Have abnormal laboratory test results: hemoglobin<9.5 gms/dl, serum creatinine>1.5mg/100ml, alkaline phosphatase 2X the upper limit of normal

- Have undergone an excisional and/or needle localization biopsy within 4 days prior to study drug administration

- Have undergone a PET scan within 7 days prior to study drug administration

- Have any active or previously treated second malignancy except carcinoma in situ of the uterine cervix or non-melanoma skin cancer

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Sutter Roseville Medical Center | Roseville, California, 95661, United States
H. Lee Moffitt Cancer Center and Research Institute | Tampa, Florida, 33612, United States
Location Countries

United States

Verification Date

January 2003

Condition Browse
Study Design Info

Allocation: Non-Randomized

Intervention model: Single Group Assignment

Primary purpose: Diagnostic

Masking: None (Open Label)